Información del producto
- D-Glucitol
- 1,5-anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-
- (1S)-
- (1S)-1,5-Anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol
- 1-(ß-D-Glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene
- Invokana
- JNJ 24831754ZAE
- JNJ 28431754
- JNJ 28431754AAA
- TA 7284
- Ver más sinónimos
- (1S)-1,5-Anhydro-1-C-(3-((5-(4-Fluorophenyl)-2-Thienyl)Methyl)-4-Methylphenyl)-D-Glucitol
- (1S)-1,5-Anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-<span class="text-smallcaps">D</span>-glucitol
- 1-(β-<span class="text-smallcaps">D</span>-Glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene
- 1-(β-D-glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienyl-methyl) benzene
- <span class="text-smallcaps">D</span>-Glucitol, 1,5-anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-, (1S)-
- Canaglifozin
- Jnj 24831754Zae
- Jnj 28431754
- Jnj 28431754Aaa
- Ta 7284
Applications Canagliflozin is a sodium/glucose cotransporter 2 (SGLT2) inhibitor. Canagliflozin has been shown to dose dependently reduce calculated renal threshold for glucose excretion and increase urinary glucose excretion. Canagliflozin is a candidate for the treatment of type 2 diabetes and obesity.
References Chao, E. et al.: Drug Fut., 36, 351 (2011); Sha, S. et al.: Diab. Obes. Metab., 13, 669 (2011); Kipnes, M.S.: Clin. Invest., 1, 145 (2011);
Propiedades químicas
Consulta técnica sobre: TR-C175190 Canagliflozin
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.